Welcome to our dedicated page for Zomedica news (Ticker: ZOMDF), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Zomedica Corp. (ZOMDF) is an animal health company focused on diagnostic, therapeutic, and monitoring devices for equine and companion animals. This news page aggregates company announcements, product updates, financial disclosures, and strategic communications so readers can follow how Zomedica is executing its stated growth plans in veterinary devices and services.
Recent news highlights Zomedica’s work across multiple platforms. The company has reported launches and expansions within its TRUFORMA in-clinic diagnostic platform, including an equine progesterone assay for reproductive management and feline validation for its multiplexed cobalamin and folate assay. It has also announced enhancements to its VETGuardian Zero Touch monitoring platform through the VETGuardian PLUS monitor, which adds a built-in display, remote viewing, and imaging features to support workflow efficiency in clinics.
On the therapeutic side, Zomedica has issued press releases about the Assisi Loop Lounge tPEMF therapy bed, positioned as an evidence-based, non-pharmaceutical option for pain and inflammation, and has continued to emphasize the role of its PulseVet shock wave system in musculoskeletal healing. News items also cover distribution agreements, such as an expanded partnership with Grovet b.v. in Europe, and collaborations that raise awareness of its Assisi and Calmer Canine technologies.
Investors can also find coverage of Zomedica’s quarterly financial results, including segment performance across diagnostics, therapeutic devices, and development services, as well as liquidity and margin commentary. Regular “Fourth Friday at Four” webinars and related special sessions are announced through press releases, providing additional context on strategy, product platforms, and business performance. Bookmark this page to review Zomedica’s ongoing disclosures and corporate developments over time.
Zomedica (OTCQB:ZOMDF) has announced significant enhancements to its equine insulin assay for the TRUFORMA Diagnostic Platform. The update features an extended dynamic range, increased by 60% from its previous version, and introduces an innovative automatic sample dilution function. This advancement allows veterinarians to measure insulin levels at the highest ranges without additional steps or increased time-to-result.
The new automatic dilution feature eliminates the need for manual dilution protocols for samples exceeding 250 µU/mL, streamlining the testing process. The enhancement maintains test consistency while freeing staff from additional tasks. This development positions TRUFORMA as having the widest dynamic range available both at Point of Care and compared to Reference Labs.
Zomedica Corp. (OTCQB:ZOMDF) has announced the launch of a new monthly webinar series called "Fourth Friday at Four" starting May 23rd, 2025. The series aims to showcase the company's innovative veterinary health products and technologies to investors, veterinarians, and industry partners.
The webinars will highlight Zomedica's product portfolio including the PulseVet® Shock Wave system for musculoskeletal healing, Assisi Loop® and Calmer Canine for pain management and anxiety, TRUFORMA® diagnostic platform, TRUVIEW® Digital Cytology System, VETGuardian® monitoring system, and VETIGEL® hemostatic gel. CEO Larry Heaton emphasized that the series will focus on building a community of professionals while providing insights into the company's technologies and growth strategy.
- Therapeutics revenue reached $5.9M (+8% YoY) - Consumables revenue grew to $4.5M (+13% YoY) - International sales increased 32% YoY - Cash position of $64.6M as of March 31, 2025
However, the company recorded a significant net loss of $63.8M, primarily due to a non-cash impairment charge of $55.8M triggered by market capitalization decline. Excluding this charge, adjusted operating expenses were $13.2M, down 9% YoY. The diagnostics segment saw a 25% revenue decline to $0.6M, mainly due to non-recurring initial distribution orders from the previous year.
Zomedica (OTCQB:ZOMDF) has launched the Equine Asthma Clinical Registry, a groundbreaking program utilizing PulseVet® shock wave therapy as a non-invasive, drug-free treatment for equine asthma. The initiative aims to gather real-world clinical evidence on the effectiveness of electrohydraulic extracorporeal shock wave therapy (ESWT) in treating respiratory conditions in horses.
Initial studies show promising results, with 58 horses completing treatment without adverse events. The registry allows veterinary clinics to enroll up to 20 horses, requiring three scheduled visits over 4-6 weeks. Equine asthma affects approximately 15% of horses over age seven, impacting their performance and quality of life. The program offers participating clinics product credits while contributing to vital research in advancing equine respiratory care.
Zomedica Corp. (ZOMDF), a veterinary health company specializing in point-of-care diagnostic and therapeutic products for equine and companion animals, has scheduled its Q1 2025 earnings conference call for Thursday, May 15, 2025, at 4:30 p.m. ET. The call will cover operational and financial highlights for the quarter ended March 31, 2025, followed by a Q&A session.
Participants can join via phone at +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (International). A replay will be available until May 29, 2025, accessible by dialing +1-844-512-2921 (U.S.) or +1-412-317-6671 (International) with pin 1148151.
Zomedica (OTCQB:ZOMDF) reported strong financial results for Q4 and full-year 2024. The company achieved record Q4 revenue of $7.9 million (8% growth) and full-year revenue of $27.3 million (8% increase from 2023). Notable highlights include:
The Diagnostics segment showed exceptional growth of 109% year-over-year, driven by TRUFORMA® and VETGuardian® product lines. The company maintained a robust gross margin of 70% and ended the year with $71.4 million in liquidity.
Despite the revenue growth, Zomedica reported a net loss of $7.2 million for Q4 and $47.0 million for the full year. The company's operating expenses increased to $70.1 million in 2024, up 16% from 2023. Looking ahead to 2025, Zomedica plans to focus on the equine market through new product launches and distribution agreements, including Vetigel® hemostatic gel.